This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: L12.1 | Special Copayment Reduction: V212 (rare disease) |
| B. Synonyms | Cicatricial pemphigoid | benign mucous membrane pemphigoid |
| C. Adult onset | Likelihood of first onset in adulthood: very high — cicatricial pemphigoid is mainly first diagnosed in adults in their 50s~70s, and is often confirmed years later because of conjunctival scarring or recurrent oral erosions, so adult onset is typical. |
| 1. History | Cicatricial pemphigoid (Cicatricial Pemphigoid, CP; or Mucous Membrane Pemphigoid,… |
| 2. Causes | Cicatricial pemphigoid is caused by IgG, IgA, or IgG+IgA autoantibodies against the dermal-epidermal junction (DEJ) or basement membrane component proteins… |
| 3. Genetics | Cicatricial pemphigoid is a complex genetic disorder in which HLA class II genes are the main genetic risk factors. Several studies have reported HLA-D… |
| 4. General epidemiology | Among autoimmune blistering diseases, cicatricial pemphigoid is rarer than bullous pemphigoid, with an annual incidence of about 1~… |
| 5. Pathophysiology | The core pathophysiology of cicatricial pemphigoid is autoantibody-mediated basement membrane damage against basement membrane antigens, recurrent inflammation, and the resulting scar formation… |
| 6. Symptoms | Cicatricial pemphigoid mainly involves mucous membranes, and skin involvement is much rarer than in bullous pemphigoid. The oral mucosa is most commonly involved (… |
| 7. Signs | On physical examination, intraoral desquamative gingivitis (gingival epithelium peels off easily), mucosal erosions with white scars, and cicatricial contraction of the buccal mucosa are observed… |
| 8. Screening | Screening for cicatricial pemphigoid is performed in patients with recurrent oral erosions (especially desquamative gingivitis), conjunctival scarring, or nasal·laryngeal·esophageal mucosal lesions… |
| 9. Diagnosis | Diagnosis of cicatricial pemphigoid is made by integrating clinical findings, histopathology, DIF, and serum antibody testing. On mucosal biopsy, subepidermal (submucosal… |
| 10. Treatment | Treatment of cicatricial pemphigoid is staged by disease severity (mild: oral only; moderate: eye·nasal·genital; severe: progressive conjunctival scarring, laryngeal·tracheal invol… |
| 11. Prognosis | The prognosis of cicatricial pemphigoid varies greatly with the sites involved. The oral-only form responds relatively well to treatment and has a favorable prognosis.… |
| 12. Prevention | The key to preventing cicatricial pemphigoid is early diagnosis and starting treatment before scarring forms. In patients with desquamative gingivitis or recurrent oral erosions… |
| 13. References | 10 papers in major international journals. |
Cicatricial pemphigoid (Cicatricial Pemphigoid, CP; or Mucous Membrane Pemphigoid, MMP) is a rare autoimmune blistering disease that mainly involves mucous membranes and causes cicatricial complications. From the late 19th~early 20th century, European dermatologists and ophthalmologists began to describe it as a disease entity with cicatricial lesions of the ocular conjunctiva accompanied by oral erosions. Initially, in ophthalmology, it was called 'benign mucous membrane pemphigoid' or 'cicatricial pemphigus'.
Its immunopathological basis was established in the 1970s~80s. Direct immunofluorescence showed linear IgG and IgA deposition along the basement membrane zone, revealing it to be an autoimmune blistering disease of the bullous pemphigoid family. Subsequently, multiple target antigens were discovered, including BP180 (C-terminal domain epitopes outside NC16A), BP230, laminin-332 (formerly laminin-5), α6β4 integrin, and type XVII collagen, which are involved variably from patient to patient. In particular, patients positive for anti-laminin-332 antibodies have a significantly higher rate of associated internal malignancy (especially lung cancer and gastric cancer), which is of great clinical importance.
At a 2002 international expert consensus, it was proposed that this disease, which had been called by various names, be unified under the name 'Mucous Membrane Pemphigoid (MMP)', but both names are still used interchangeably today. Treatment uses dapsone, steroids, immunosuppressants, and rituximab, and ophthalmologic co-management to prevent conjunctival scarring is central to treatment.
Cicatricial pemphigoid is caused by IgG, IgA, or IgG+IgA autoantibodies against the dermal-epidermal junction (DEJ) or basement membrane component proteins. Target antigens sometimes overlap with those of bullous pemphigoid (BP), but a more diverse range of autoantigens is involved in cicatricial pemphigoid. The main target antigens are ① the C-terminal domain of BP180 (COL17A1) (region outside NC16A), ② BP230 (BPAG1), ③ laminin-332 (α3β3γ2 heterotrimer), ④ α6β4 integrin, and ⑤ type VII collagen (COL7A1, overlapping with epidermolysis bullosa acquisita). Among these, the incidence of internal malignancy is markedly higher in the patient group with IgG anti-laminin-332 antibodies, so tumor screening is essential when this autoantibody is detected.
The clinical phenotype is reported to differ somewhat depending on which antigen the autoantibodies target. For example, anti-laminin-332-positive patients tend to have more frequent conjunctival involvement and more severe scarring. As in other pemphigoid-family diseases, the autoantibody-driven mechanism is explained by basement membrane damage through complement activation, recruitment of neutrophils·eosinophils, and secretion of proteolytic enzymes, together with a recurrent inflammation-scarring cycle. Reported genetic predispositions include associations with HLA-DQB1*03:01, HLA-DR4, DR11, and DPw4, and some drugs (penicillamine, practolol) may act as environmental triggers.
Cicatricial pemphigoid is a complex genetic disorder in which HLA class II genes are the main genetic risk factors. Several studies have reported associations with HLA-DQB1*03:01, the HLA-DRB1*04 group, HLA-DPw4, and others. HLA association data in East Asian patients are limited and may differ somewhat from Western populations. Pathogenic variants in the target antigen genes themselves (COL17A1, LAMA3, LAMB3, LAMC2, ITGA6, ITGB4) are not a direct cause of this disease. The clinical significance of genetic counseling is very limited, and familial clustering is rare.
Among autoimmune blistering diseases, cicatricial pemphigoid is rarer than bullous pemphigoid, with an estimated annual incidence of about 1~2 per million population. Onset is mainly in the 50s~70s, and many reports indicate it is more than twice as common in women as in men. The oral-only form is most common, and conjunctival involvement (ocular form, ocular MMP) is the second most common. Widespread involvement (multiple mucosae including oral·conjunctival·laryngeal·esophageal·nasal·anogenital) is associated with a severe prognosis. Accurate epidemiological statistics are limited in Korea, but diagnosis·management is carried out through the rare disease registration system.
The core pathophysiology of cicatricial pemphigoid is autoantibody-mediated basement membrane damage against basement membrane antigens, recurrent inflammation, and the resulting scar formation. When autoantibodies bind to basement membrane component proteins, the complement pathway is activated, and neutrophils and eosinophils are recruited to local tissue by C5a. Proteolytic enzymes secreted by these inflammatory cells (elastase, MMP-9, cathepsin G) degrade laminin-332, anchoring fibrils (COL7A1), and hemidesmosomes of the basement membrane, causing epidermal-dermal or mucosal-submucosal separation. In the repeated inflammation-regeneration cycle, TGF-β, PDGF, and others activate fibroblasts, leading to excessive collagen accumulation (scarring). Recurrent inflammation in the conjunctiva can progress to shortening of the conjunctival fornix, symblepharon, corneal vascularization, and blindness.
Cicatricial pemphigoid mainly involves mucous membranes, and skin involvement is much rarer than in bullous pemphigoid. The oral mucosa is most commonly involved (about 85%), characterized by painful erosions, desquamative gingivitis, and erosions of the buccal mucosa·hard palate. Desquamative gingivitis is often misdiagnosed as periodontal disease. Conjunctival involvement occurs in about 25~30% and initially presents as chronic conjunctivitis, discharge, redness, conjunctival scarring, and similar findings. Conjunctival scarring progresses to fornix shortening, symblepharon, entropion, and trichiasis, and without treatment leads to corneal opacity and blindness. Nasal mucosal involvement causes epistaxis, intranasal crusting, and nasal septal perforation, and laryngeal·tracheal involvement carries a risk of airway obstruction, making it an emergency. Esophageal involvement causes stricture and dysphagia.
On physical examination, intraoral desquamative gingivitis (gingival epithelium peels off easily), mucosal erosions with white scars, and cicatricial contraction of the buccal mucosa are observed. On conjunctival examination (slit-lamp microscopy), conjunctival injection, adhesions, fornix shortening, entropion, and trichiasis are the main signs. Tissue can be sampled from the conjunctival surface for DIF, but because of the risk of worsening scarring it is performed by experienced clinicians. Skin lesions may appear as tense blisters on the head·face·trunk and leave scars after healing. Laboratory tests used for diagnosis include anti-BP180 ELISA (NC16A negative, C-terminal possibly positive), anti-laminin-332 ELISA, anti-α6β4 integrin testing, and DIF (linear IgG·IgA·C3 along the basement membrane zone).
Screening for cicatricial pemphigoid is performed in patients with recurrent oral erosions (especially desquamative gingivitis), conjunctival scarring, or nasal·laryngeal·esophageal mucosal lesions. Serologic tests include anti-BP180 ELISA (NC16A and C-terminal domain), anti-laminin-332 ELISA, anti-BP230 ELISA, and IIF (NaCl-split skin). If anti-laminin-332 antibody is positive, malignancy screening (chest CT, upper endoscopy, colonoscopy, etc.) is mandatory. Biopsy DIF is performed on normal mucosa adjacent to a lesion, and conjunctival DIF is decided carefully in view of the risk of worsening scarring. On IIF, fluorescence on the epidermal side of the NaCl-split skin substrate suggests cicatricial pemphigoid (BP180/laminin-332 autoantibodies).
Diagnosis of cicatricial pemphigoid is made by integrating clinical findings, histopathology, DIF, and serum antibody testing. Histopathologic findings on mucosal biopsy are subepidermal (submucosal) blisters and neutrophil·eosinophil infiltration along the basement membrane zone. DIF shows linear IgG, IgA, or IgG+IgA deposition along the basement membrane zone, often accompanied by C3. Unlike bullous pemphigoid (BP180 NC16A as the main epitope), anti-BP180 ELISA is often negative in cicatricial pemphigoid, so additional testing for non-NC16A epitopes, laminin-332, and α6β4 integrin is needed. Multidisciplinary evaluation by ophthalmology (conjunctival slit-lamp examination, conjunctival DIF, visual acuity assessment), otorhinolaryngology (laryngoscopy, esophagoscopy), and urology (if the urethra is involved) is essential to assess conjunctival involvement.
Treatment of cicatricial pemphigoid is staged by disease severity (mild: oral only; moderate: eye·nasal·genital; severe: progressive conjunctival scarring, laryngeal·tracheal involvement). Dapsone 50~200 mg/day is first-line treatment for mild~moderate disease and suppresses mucosal inflammation through its anti-neutrophil effect. Systemic corticosteroids (prednisolone 0.5~1 mg/kg/day) are used for acute exacerbations and moderate~severe disease. Steroid-sparing immunosuppressants used include azathioprine, mycophenolate mofetil, cyclophosphamide (severe conjunctival involvement), and methotrexate. Rituximab has been reported to be effective in relapsing·refractory cicatricial pemphigoid. To halt progression of conjunctival scarring, ophthalmology may consider topical MMC (mitomycin C), ocular prosthesis insertion, mucosal grafting, and similar measures. With laryngeal·tracheal involvement, immediate otorhinolaryngology consultation and preparation for airway management are essential.
The prognosis of cicatricial pemphigoid varies greatly with the sites involved. The oral-only form responds relatively well to treatment and has a favorable prognosis. In the conjunctival form (ocular MMP), progression to blindness due to progressive scarring despite treatment is reported in about 10~20%, and early diagnosis and aggressive treatment are decisive for preserving vision. Laryngeal·tracheal involvement can be life-threatening through airway obstruction. Anti-laminin-332-positive patients may have a poor prognosis because of increased malignancy risk and require regular tumor screening. Because scarring is irreversible, suppressing inflammation with early treatment is key to preventing scarring.
The key to preventing cicatricial pemphigoid is early diagnosis and starting treatment before scarring forms. In patients with desquamative gingivitis or recurrent oral erosions, early immunopathological testing is performed through dental-dermatology collaboration. Patients with suspected conjunctival involvement need immediate ophthalmology referral, and regular monitoring of the conjunctival status allows early detection of scarring progression. Infection prevention during immunosuppressive therapy (vaccination, oral hygiene, ocular lubrication) is important. Annual tumor screening is recommended in anti-laminin-332-positive patients. Before dapsone use, G6PD deficiency should be checked, and blood counts and liver function are monitored regularly.